Ersen Ömer, Koca Kenan, Akpancar Serkan, Seven Mehmet Murat, Akyıldız Faruk, Yıldız Yavuz, Özkan Hüseyin
Department of Orthopedics and Traumatology, Gulhane Training and Research Hospital, Ankara, Turkey.
Department of Sports Medicine, Gulhane Training and Research Hospital, Ankara, Turkey.
Turk J Phys Med Rehabil. 2017 Aug 12;64(1):59-65. doi: 10.5606/tftrd.2018.944. eCollection 2018 Mar.
This study aims to evaluate the efficacy of prolotherapy injections for the treatment of plantar fasciitis.
Between October 2014 and October 2015, 60 patients with symptomatic chronic plantar fasciitis were randomly divided into two groups, as control (n=31) and prolotherapy (n=29) groups. In the prolotherapy group, ultrasound-guided prolotherapy injections into the plantar fascia up to five different points were performed three times every 21 days. In the control group, the patients received instructions for plantar fascia and Achilles tendon stretching exercises three times a week for three months. Additionally, all patients were given heel lifts and instructed to refrain from heavy loading activity. The patients were evaluated via the Visual Analog Scale (VAS), Food and Ankle Outcome Score (FAOS), and Foot Function Index (FFI) at baseline and at 21, 42, 90, and 360 days during follow-up.
A total of 50 patients completed follow-up (26 patients in the prolotherapy group and 24 patients in the control group). The VAS, FAOS, and FFI scores were significantly improved in both groups (p<0.001). There were no statistically significant differences in the pain and functional scores at 21 days of treatment between the groups. The VAS and FAOS scores were higher in the prolotherapy group than the control group at 42, 90, and 360 days of treatment. The FFI scores were also higher in the prolotherapy group than the controls at 42 and 90 days of treatment; however, both groups had similar scores at 360 days.
Our study results suggest that prolotherapy is an effective auxiliary method for treating chronic plantar fasciitis.
本研究旨在评估注射增殖疗法治疗足底筋膜炎的疗效。
2014年10月至2015年10月，60例有症状的慢性足底筋膜炎患者被随机分为两组，即对照组（n = 31）和增殖疗法组（n = 29）。在增殖疗法组中，在超声引导下向足底筋膜最多五个不同点进行注射增殖疗法，每21天进行三次。在对照组中，患者接受足底筋膜和跟腱拉伸练习的指导，每周三次，共三个月。此外，所有患者都使用了足跟垫，并被要求避免重负荷活动。在基线以及随访期间的第21、42、90和360天，通过视觉模拟量表（VAS）、足与踝关节结果评分（FAOS）和足部功能指数（FFI）对患者进行评估。
共有50例患者完成随访（增殖疗法组26例，对照组24例）。两组的VAS、FAOS和FFI评分均显著改善（p<0.001）。两组在治疗21天时的疼痛和功能评分无统计学显著差异。在治疗42、90和360天时，增殖疗法组的VAS和FAOS评分高于对照组。在治疗42和90天时，增殖疗法组的FFI评分也高于对照组；然而，两组在360天时的评分相似。
我们的研究结果表明，注射增殖疗法是治疗慢性足底筋膜炎的一种有效辅助方法。
